- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01988077
Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients
April 3, 2019 updated by: Dr. Jacob Schachter MD,, Sheba Medical Center
Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for the Treatment of Metastatic Melanoma Patients
A rationally designed combination of adoptive T cell therapy and ipilimumab could strongly increase the proportion of CR patients, as well as the durability of response, as compared to ipilimumab or TIL alone.
The investigators hypothesize that the combination of those two important modalities could result in a durable (≥ 1 year) complete response rate of 30% in stage IV melanoma patients.
Study Overview
Status
Terminated
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ramat Gan, Israel, 52621
- Sheba. Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women, ≥ 18 years of age.
- Measurable metastatic melanoma (defined histologically) with at least one lesion that is resectable for TIL generation:
- Patients with asymptomatic brain metastases are allowed
- Previously treated or untreated unresectable stage III or stage IV melanoma
- Clinical performance status of ECOG 0 or 1.
Laboratory:
- ANC ≥ than 1000 k/microL without support of filgrastim
- WBC > 3000 k/microL
- Hemoglobin greater than 8.0 g/dL
- Platelet count greater than 100,000 K/microL
- Seronegative for HIV, HBV, HCV
- Serum ALT/AST less than three times the upper limit of normal.
- Serum creatinine less than or equal to 1.6 mg/dL.
- Total bilirubin less than or equal to 2 mg/dL, except in patients with Gilbert's syndrome who must have a total bilirubin less than 3 mg/dl.
- An interval of at least 28 days since last oncological treatment to the first ipilimumab course. Palliative radiation therapy outside of the brain or therapeutic radiation to the brain after the patient's condition is stabilized and systemic steroids required for the management of systems due to brain metastases is decreased to the lowest fixed dose possible does not require 28-day waiting period.
- Negative pregnancy test in women of child bearing potentialwithin 72 hours before the start of ipilimumab.
- Willing to practice effective birth control during treatment and for 26 weeks after receiving the last dose of ipilimumab (both women of child bearing potential and men of fathering potential).
- Life expectancy greater than three months.
Exclusion Criteria:
- Failure to meet all of the inclusion criteria.
- Autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (eg, rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [eg, Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome and Myasthenia Gravis).
- Active concurrent malignant disease, or disease-free for less than 5 years (exception: adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix)
- Patients receiving any non-oncology vaccine therapy used for prevention of infectious diseases for up to 4 weeks before or after any dose of ipilimumab with the exception of amantadine and flumadine, will not be eligible for ipilimumab treatment.
- Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of ipilimumab hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea.
- Active systemic infections, coagulation disorders or other active major medical illnesses:
Cardiovascular:
- History of coronary revascularization or ischemic symptoms
- Clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block
- Left ventricular EF of 45% or less.
- Respiratory:
- Documented FEV1 less than or equal to 70% tested in patients with symptoms of respiratory dysfunction
- Immune system
- Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS)
- Hepatitis B and C infection, regardless of the control on antiviral therapy
- Opportunistic infections
- Any subject who has a life-threatening condition that requires high-dose immunosuppressant(s).
- A history of prior treatment with ipilimumab or prior CD137 agonist or CTLA 4 inhibitor or agonist
- History of severe immediate hypersensitivity reaction to any of the agents used in this study.
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious) illness.
- Women of child-bearing potential:
- Pregnant, breastfeeding, or unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 8 weeks after cessation of study drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Adoptive cell transfer combined with Ipilimumab
|
Adoptive cell transfer
2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the response rate of the combination of ipilimumab with young TIL protocol and the CR rate of this combination according to modified RECIST 1.1.
Time Frame: October 2017
|
October 2017
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
• Evaluate the toxicity of this treatment regimen.
Time Frame: Follow up for 1 year
|
Toxicity will be reported by type and severity according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 4.
|
Follow up for 1 year
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine duration of response
Time Frame: follow up for 1 year
|
follow up for 1 year
|
Determine overall survival
Time Frame: follow up for 1 year
|
follow up for 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jacob Schachter, Prof., Sheba Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (Actual)
May 20, 2016
Study Completion (Actual)
October 25, 2018
Study Registration Dates
First Submitted
October 24, 2013
First Submitted That Met QC Criteria
November 13, 2013
First Posted (Estimate)
November 20, 2013
Study Record Updates
Last Update Posted (Actual)
April 5, 2019
Last Update Submitted That Met QC Criteria
April 3, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Ipilimumab
Other Study ID Numbers
- Ipilimumab TIL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
to be decided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adoptive cell transfer
-
Sheba Medical CenterUnknownMetastatic MelanomaIsrael
-
Ain Shams UniversityNot yet recruitingType 1 Diabetes Mellitus | Lupus NephritisEgypt
-
CytoMed Therapeutics Pte LtdUnknownSarcoma | Nasopharyngeal Carcinoma | Gastric Cancer | Colorectal Cancer | Prostate Cancer | Triple Negative Breast CancerMalaysia
-
Jinan University GuangzhouGuagnzhou Qiaokang HospitalUnknownAdoptive Treatment for Hepatitis B With γδT CellsChina
-
suhaichuanShanghai Biomed-union Biotechnology Co., Ltd.RecruitingChemotherapy | Advanced Non-small Cell Lung CancerChina
-
University of ZurichCompletedMalignant Pleural MesotheliomaSwitzerland
-
GlaxoSmithKlineRecruitingNeoplasmsUnited States, Spain, Italy, Netherlands, Canada, Australia, Germany, United Kingdom
-
Chinese PLA General HospitalCompletedHepatocellular CarcinomaChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Cholangiocarcinoma | Metastatic... and other conditionsUnited States